In January 2026, one negotiation set Medicare's price for Eliquis at $231 a month — against a $346 sticker today and $521 in 2023. Same pill. So somebody was choosing that number all along. This capstone follows the rebate chain, the middlemen, and the patent wall, with the insulin, EpiPen, inhaler and GLP-1 stories as evidence. Every figure dated and sourced.
Researched with AI assistance; every figure is checked against the primary source cited on this page before publishing. How we work →
This is a capstone, so the table follows the machine instead of a map: each row is one link in the chain that turns a factory price into your copay. Figures come from CMS's negotiated-price fact sheet, Bristol Myers Squibb's current price page, FTC staff reports and complaint filings, GAO audits, peer-reviewed journals, a federal appeals-court opinion, a KFF poll, and RAND/ASPE international comparisons — each anchored to the year of the underlying data.
| Link in the chain | Figure | Context | Source |
|---|---|---|---|
| The sticker — manufacturers | $231 for Medicare (list: $346) | Eliquis, the blood thinner nearly 4 million Medicare patients used in 2023: $521 was the 2023 list price for a 30-day supply; $231 is the negotiated price Medicare has paid since January 1, 2026 — the first negotiated prices in the program's history. (As of January 2026, its maker's own list price is $346 — so Medicare pays about a third below today's sticker.) Ten drugs came in 38–79% below their 2023 list prices (Januvia the deepest at 79%), and CMS projected about $1.5 billion in savings for people with Part D coverage in 2026. Nothing about the pills changed. | CMS (2023 list prices; effective Jan 2026) · Bristol Myers Squibb (current list price) |
| The middlemen — PBMs | ~80% of 6.6B prescriptions | Three pharmacy benefit managers processed nearly 80% of the 6.6 billion prescriptions Americans filled in 2023 — each inside a conglomerate that also owns a major insurer and its own pharmacies (FTC, 2024). Per the FTC's insulin complaint, they are paid rebates and fees calculated as a percentage of the list price: the higher the sticker, the bigger the cut, with no extra service provided. FTC investigators also reported their affiliated pharmacies collected an estimated $7.3 billion above drug acquisition cost on specialty generics, 2017–2022. | FTC reports (2024–2025) |
| The counter — your copay | ~4× what plans paid | Government auditors found Part D copays are calculated on the gross price before rebates. On 79 of the 100 most-rebated drugs, payments by or on behalf of beneficiaries (59% of it Medicare's low-income subsidy) were about 4 times what their plans paid net (GAO, 2021 data) — while roughly $48.6 billion in manufacturer rebates flowed back through Medicare drug plans that same year. Since 2025 a yearly out-of-pocket cap ($2,100 in 2026) limits what a Part D patient pays. | GAO (2021 data) |
| The drift — list vs net | +159% vs +60% | One peer-reviewed analysis tracked 602 branded drugs from 2007 to 2018: list prices rose 159% while the net prices actually paid rose 60%, both adjusted for inflation (JAMA). US brand-name manufacturer prices ran 4.22× those of 33 other countries combined (about 3.1× after RAND's rebate adjustment) — yet US unbranded generics sat at 67% of the international level, cheaper than the world's (RAND/ASPE, 2022 data). Where competition reaches, the system produces lower prices. | JAMA (2007–2018) · RAND/ASPE (2022 data) |
| The wall — patents | 132 patents on one drug | Humira was shielded by 132 patents on top of its original one; Europe got biosimilar copies in 2018 while Americans waited until 2023. By 2021 its US list price had climbed roughly 470% since launch (7th Circuit · House Oversight). One study found that 78% of the drugs gaining new patent protection in 2005–2015 were existing drugs, and regulators have challenged over 400 improper Orange Book patent listings since 2023 — a single wrong listing can freeze a generic for 30 months (FTC). | 7th Cir. (2022) · House Oversight (2021) · J. Law & Biosciences · FTC |
| The catch — who feels it | Medicare-first | Fifteen more negotiated prices follow in January 2027, semaglutide among them (CMS). A February 2026 law de-links PBM Part D pay from list prices starting 2028 and requires 100% rebate pass-through to employer plans for plan years starting 30 months after enactment (August 2028 or later). But it starts with Medicare — most prescriptions won't feel it today, and in a March 2026 KFF poll 43% of adults said they had not taken a medicine as prescribed in the past year because of cost (19% cut pills or skipped doses). | CMS · P.L. 119-75 (Feb 2026) · KFF poll (Mar 2026) |
We compare what prescriptions cost and how those numbers were set — not what anyone should take, start, stop, or switch. Treatment decisions belong with you, your pharmacist, and a licensed prescriber.
The sticker and the real price parted ways a generation ago. A peer-reviewed JAMA analysis tracked branded drugs for eleven years, 2007–2018: list prices rose 159% while the prices actually paid — after the discounts nobody sees — rose 60%, both adjusted for inflation. The person the sticker still binds is the patient: government auditors found Part D copays were calculated on the gross price before rebates, and on 79 of the 100 most-rebated drugs, payments by or on behalf of beneficiaries were about 4 times what their plans paid net (GAO, 2021 data). The discount was real. It just wasn't for them.
The mechanism came out in an FTC complaint over insulin: the companies that help decide which drugs insurance covers are paid rebates and fees calculated as a percentage of the list price — the higher the sticker, the bigger their cut, with no extra service provided (FTC allegation). Three of those companies processed nearly 80% of the 6.6 billion prescriptions Americans filled in 2023, each inside a conglomerate that also owns a major insurer and its own pharmacies. FTC investigators further reported that pharmacies owned by those three marked up specialty generics — cancer pills, transplant drugs — by hundreds, sometimes thousands of percent, collecting an estimated $7.3 billion above acquisition cost between 2017 and 2022. In February 2026, Express Scripts settled with the FTC, agreeing to price patients' shares on the net number rather than the sticker; Caremark followed in July 2026, and the third, OptumRx, had its case pulled from adjudication in June to consider a settlement.
A bluff this large survives only where competition can't reach — and the door was locked with patents. Humira, for years the world's best-selling drug, was shielded by 132 patents on top of its original one; Europe got biosimilar copies in 2018 while Americans waited until 2023, and by 2021 its US list price had climbed roughly 470% since launch (7th Circuit · House Oversight). One study found that 78% of the drugs gaining new patent protection in 2005–2015 were existing drugs — new shell, old medicine, the same pattern this channel documented in the EpiPen (a $608 list price in 2016, about $225 for a generic two-pack at pharmacy cost today) and the inhaler that costs US pharmacies about $497 and whose patents reportedly sit on the plastic device. The FTC once estimated pay-for-delay deals cost consumers about $3.5 billion a year, and since 2023 regulators have challenged more than 400 improper Orange Book patent listings — because a single wrong listing can freeze a generic for 30 months. Meanwhile, US unbranded generics sold at 67% of the international level (RAND/ASPE, 2022 data): where competition reached, the system produced lower prices.
The first ten negotiated Medicare prices took effect January 1, 2026 — 38 to 79% below their 2023 list prices, with CMS projecting about $1.5 billion in savings for people on Part D that year and Eliquis's $521-to-$231 drop the headline case (CMS; as of January 2026, Eliquis's own list price is $346). Fifteen more drugs follow in January 2027, semaglutide among them. And a February 2026 law ordered the rebate game unwound: from 2028, PBM pay in Medicare Part D is de-linked from list prices, and for employer plans a rule that every rebate must reach the plan phases in for plan years starting 30 months after enactment (August 2028 or later). The honest asterisk stays: it starts with Medicare, most prescriptions won't feel it today, and in a March 2026 KFF poll 43% of adults said cost had led them not to take a medicine as prescribed in the past year.
This capstone didn't start from theory. Each mechanism above was documented drug-by-drug in this series first — five cost investigations, each with its own dated sources. They are the evidence; this page is the machine they add up to.
No single actor. Manufacturers set the list price, pharmacy benefit managers negotiate rebates calculated as a percentage of that list, and insurers set the patient's share. The FTC's insulin complaint alleges that higher stickers meant bigger rebates and fees for the middlemen, with no extra service provided — so the middlemen's pay rose with the sticker, and the person at the counter got none of it.
A PBM works with your health plan to decide which drugs it covers and what you pay for each. Three of them processed nearly 80% of the 6.6 billion prescriptions Americans filled in 2023 — each inside a conglomerate that also owns a major insurer and its own pharmacies (FTC, 2024).
Government auditors found Medicare Part D copays are calculated on the gross price before rebates. On 79 of the 100 most-rebated drugs, payments by or on behalf of beneficiaries (59% of it Medicare's low-income subsidy) were about 4 times what their plans paid net (GAO, 2021 data), while about $48.6 billion in manufacturer rebates flowed through Part D plans that year.
Medicare's first ten negotiated prices took effect January 1, 2026 — 38–79% below 2023 list prices, with Eliquis going from a $521 list price in 2023 to $231 (its list price is $346 as of January 2026) and CMS projecting about $1.5 billion in savings for people with Part D (CMS). Fifteen more drugs follow in 2027, semaglutide included, and a February 2026 law de-links PBM pay from list prices in Medicare Part D starting 2028, with 100% rebate pass-through to employer plans for plan years starting 30 months after enactment (August 2028 or later).
Patents — often on delivery devices or minor variations rather than the medicine itself. Humira carried 132 patents on top of its original one, and US biosimilars arrived 5 years after Europe's (7th Circuit; J. Law & Biosciences). One study found that 78% of the drugs gaining new patent protection in 2005–2015 were existing drugs, and regulators have challenged over 400 improper patent listings since 2023 (FTC).
No — and that's the tell. US brand-name drug prices ran 4.22× those of 33 other countries combined (about 3.1× after RAND's rebate adjustment), but US unbranded generics sat at 67% of the international level — cheaper than the world's (RAND/ASPE, 2022 data). Where real competition reaches, the American system produces lower prices; the gap lives where it can't.
In a KFF poll fielded February 24 to March 2, 2026, 43% of adults said that in the past year they had not taken a medicine as prescribed because of cost: 31% took an over-the-counter drug instead, 27% didn't fill a prescription, and 19% cut pills in half or skipped doses. (The FTC's 2024 report cited a 2023 KFF figure of nearly 30%.) The 2026 negotiated prices start with Medicare, so most prescriptions won't feel them immediately. Cost information, not medical advice — treatment decisions belong with you and a licensed prescriber.
Wellness Vision does not sell medication, book trips, or take referrals. Every figure above traces to the public sources cited — federal fact sheets, FTC staff reports and complaint filings, GAO audits, peer-reviewed journals, and congressional records. This is a cost and policy explainer, not medical advice: nothing here tells anyone to start, stop, switch, or ration a medication, and treatment decisions belong with you, your pharmacist, and a licensed prescriber.
📋 Or get the free Medical Travel Cost Checklist — no email →
View provenance manifest for this video →
You shouldn't have to go broke to feel whole.
